Table 6 Type of vaccine and doses used among patients developed post-vaccine COVID-19 infection (group B) versus vaccinated participants who did not develop infection group A
From: Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt
COVID-19 vaccinated cases (n = 369) | P value* | ||
|---|---|---|---|
Group A (n = 299) | Group B (n = 70) | ||
Type of vaccine | < 0.001 | ||
AstraZeneca | 76 (25.4%) | 31 (44.3%) | |
Sinofarm | 87 (29.1%) | 16 (22.9%) | |
Sinovac | 110 (36.8%) | 14 (20%) | |
Johnson | 5 (1.7%) | 1 (1.4%) | |
Pfizer | 15 (5%) | 5 (7.1%) | |
Moderna | 5 (1.7%) | 0 | |
Sputnik | 1 (0.30%) | 3 (4.3%) | |
Dosing | < 0.001 | ||
Partially vaccinated | 33 (11%) | 17 (24.3%) | |
Fully vaccinated | 266 (89%) | 53 (75.7%) | |